According to Grandview Research, the hybrid and decentralized clinical trial (DCT) market will be worth more than $12B by 2030. Sponsors and CROs are taking lessons learned during current DCTs to develop new strategies that create sustainable, repeatable, and effective clinical conduct. These new strategies should enable organizations to create and own partnerships, use data from past trials to accelerate the speed of research, and ease the everyday life for sites and participants.
To realize this experience, organizations must identify their own core competencies, build out strategies with partners, and deploy a unified trial platform that acts as a data steward, data analyzer, and a springboard to deploy core trial solutions such as consent, COAs, sensors and more.
In this webcast, Medable experts Sam Bavery (VP, Strategy & Growth), Paul O’Malley (Growth & Strategy Lead) and Claire Marsden (SVP, Project Mgmt), discuss how sponsors and CROs can take their trial conduct to the next level to help them achieve their organizational goals.